Histogen to Present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference
Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company, announced its participation in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company, announced its participation in the H.C. Wainwright BIOCONNECT 2021 Virtual Conference. The presentation will be available for on-demand listening starting January 11, 2021, at 6:00 a.m. Eastern Time on the Investors section of the Histogen website. Histogen focuses on developing innovative restorative therapeutics using hypoxia-induced multipotent cells, targeting applications for hair growth, dermal rejuvenation, joint cartilage regeneration, and spinal disk repair.
Details
News Market Reaction – HSTO
The recorded move for HSTO in the trading session of this news was +1.06%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that it will present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference.
Presentation Details
The presentation will be available for on-demand listening beginning Monday, January 11, 2021, at 6:00 a.m. Eastern Time on the Investors section of the Histogen website at www.histogen.com, under the New and Events tab.
Webcast Link: https://journey.ct.events/view/dccb42bf-3f14-42b9-a4b2-09c945ccd06c
About Histogen
Histogen Inc. is a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. Histogen’s innovative technology platform utilizes cell conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells. Histogen’s proprietary, reproducible manufacturing process provides targeted solutions across a broad range of therapeutic indications including hair growth, dermal rejuvenation, joint cartilage regeneration and spinal disk repair. For more information, please visit www.histogen.com.
Contact:
Susan A. Knudson
Executive Vice President & CFO
Histogen Inc.
ir@histogen.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.